GLUE

Company Overview — What Does Monte Rosa Therapeutics, Inc. Do?

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. Monte Rosa Therapeutics, Inc. (GLUE) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Markus Warmuth and employs approximately 90 people. With a market capitalization of $1.4B, GLUE is one of the notable companies in the Healthcare sector.

Monte Rosa Therapeutics, Inc. (GLUE) Stock Rating — Hold (April 2026)

As of April 2026, Monte Rosa Therapeutics, Inc. receives a Hold rating with a composite score of 39.2/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.GLUE ranks #1,841 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Monte Rosa Therapeutics, Inc. ranks #186 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GLUE Stock Price and 52-Week Range

Monte Rosa Therapeutics, Inc. (GLUE) currently trades at $17.82. The stock lost $0.23 (1.3%) in the most recent trading session. The 52-week high for GLUE is $25.77, which means the stock is currently trading -30.8% from its annual peak. The 52-week low is $3.50, putting the stock 409.1% above its annual trough. Recent trading volume was 712K shares, suggesting relatively thin trading activity.

Is GLUE Overvalued or Undervalued? — Valuation Analysis

Monte Rosa Therapeutics, Inc. (GLUE) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.57x, versus the sector average of 2.75x. The price-to-sales ratio is 10.53x, compared to 1.66x for the average Healthcare stock.

At current multiples, Monte Rosa Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Monte Rosa Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Monte Rosa Therapeutics, Inc. (GLUE) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -6.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.6% versus the sector average of -33.1%.

On a margin basis, Monte Rosa Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -140.3% (sector: -66.1%). Net profit margin stands at -117.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 171.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GLUE Debt, Balance Sheet, and Financial Health

Monte Rosa Therapeutics, Inc. has a debt-to-equity ratio of 87.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 6.54x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $208M.

GLUE has a beta of 0.90, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Monte Rosa Therapeutics, Inc. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Monte Rosa Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Monte Rosa Therapeutics, Inc. reported revenue of $130M. Net income for the quarter was $-16M. Gross margin was 100.0%. Operating income came in at $-31M.

In Q3 2025, Monte Rosa Therapeutics, Inc. reported revenue of $13M. Net income for the quarter was $-27M. Revenue grew 38.5% year-over-year compared to Q3 2024. Operating income came in at $-33M.

In Q2 2025, Monte Rosa Therapeutics, Inc. reported revenue of $23M. Net income for the quarter was $-12M. Revenue grew 394.0% year-over-year compared to Q2 2024. Operating income came in at $-16M.

In Q1 2025, Monte Rosa Therapeutics, Inc. reported revenue of $85M. Net income for the quarter was $47M. Revenue grew 7882.0% year-over-year compared to Q1 2024. Operating income came in at $44M.

Over the past 8 quarters, Monte Rosa Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $1M to $130M. Investors analyzing GLUE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GLUE Dividend Yield and Income Analysis

Monte Rosa Therapeutics, Inc. (GLUE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GLUE Momentum and Technical Analysis Profile

Monte Rosa Therapeutics, Inc. (GLUE) has a momentum factor score of 70/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

GLUE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Monte Rosa Therapeutics, Inc. (GLUE) ranks #186 out of 838 stocks based on the Blank Capital composite score. This places GLUE in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GLUE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GLUE vs S&P 500 (SPY) comparison to assess how Monte Rosa Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

GLUE Next Earnings Date

No upcoming earnings date has been announced for Monte Rosa Therapeutics, Inc. (GLUE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GLUE? — Investment Thesis Summary

Monte Rosa Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 17/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Price momentum is positive at 70/100, suggesting the trend favors buyers. High volatility (stability score 37/100) increases portfolio risk.

In summary, Monte Rosa Therapeutics, Inc. (GLUE) earns a Hold rating with a composite score of 39.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GLUE stock.

Related Resources for GLUE Investors

Explore more research and tools: GLUE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GLUE head-to-head with peers: GLUE vs AZN, GLUE vs SLGL, GLUE vs VMD.